Related Experiment Video

Updated: Jan 13, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

615

CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy

Wm Kevin Kelly1, Paul Marks2, Victoria M Richon3

  • 1Division of Solid Tumor Oncology, Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center at Thomas Jefferson University. wm.kevin.kelly@jefferson.edu.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 17, 2015
PubMed

Insights

The first study of intravenous vorinostat, a histone deacetylase inhibitor, confirmed its safety and biological activity. This research paved the way for oral vorinostat and its approval for cutaneous T-cell lymphomas.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Histone deacetylase (HDAC) inhibitors represent a novel class of anticancer agents.
  • Vorinostat was the first-in-class HDAC inhibitor developed.

Purpose of the Study:

  • To establish the safety and biologic activity of intravenously administered vorinostat.
  • To evaluate vorinostat as a potential therapeutic agent for cancer.

Main Methods:

  • Intravenous administration of vorinostat.
  • Assessment of safety and biologic activity through clinical and laboratory measures.

Main Results:

  • Intravenous vorinostat was found to be safe and exhibited significant biologic activity.
  • The study confirmed the potential of vorinostat as an anticancer drug.

Conclusions:

  • Intravenous vorinostat is safe and biologically active, supporting further development.
  • This foundational study led to oral vorinostat and its subsequent approval for cutaneous T-cell lymphomas, advancing the field of HDAC inhibitors.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.7K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.4K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K